ATLANTA – Research presented today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo shows that a new test could identify healthcare professionals who are experiencing high levels of work-related stress and anxiety. As COVID-19 cases surge again, this test could play a critical role in helping healthcare professionals on the frontlines of the pandemic to get essential mental health support.
As the Delta variant of the coronavirus spreads, healthcare professionals are finding themselves right back where they were before the vaccines came out: grappling with a flood of COVID-19 patients and the challenges that entails. In some ways, this new wave of COVID-19 cases is hitting healthcare professionals even harder than previous peaks due to the fact that many are still struggling with depression and post-traumatic stress disorder from the pandemic’s earlier phases. Making matters worse is the fact that healthcare professionals are also severely overworked because thousands have left the field as a result of the pandemic, causing chronic staffing shortages. Not only is this taking a terrible toll on healthcare professionals’ mental welfare, but it’s also impacting the quality of care that patients receive for both COVID-19 and more routine illnesses. It is therefore vital that hospitals improve healthcare professionals’ access to mental health support.
A blood test for occupational stress could help to achieve this goal by making it easier to identify healthcare professionals who need mental health treatment. In an effort to find a biomarker that could be used for such a test, a team of researchers led by Hala Demerdash, PhD, of Alexandria University Hospitals in Egypt, set out to determine if blood levels of copeptin correlate with psychological stress. Copeptin is part of a precursor to the hormone arginine vasopressin (which is released in response to stress) that is more stable than the hormone itself. The researchers measured blood copeptin levels in 70 physicians and nurses who were treating COVID-19 patients in the ICU, and also gave the participants a psychological stress questionnaire at the same timepoints when their copeptin levels were measured.
From this, the researchers found that there was a positive correlation between blood copeptin levels and study participants’ stress questionnaire scores. Participants worked in the ICU for two weeks, followed by two weeks of isolation at home. They were actually at their most stressed right before they went into the ICU due to anticipatory anxiety, with mean blood copeptin levels of 15.67 ± 8.6 pmol/L and mean stress questionnaire scores of 66.9 ± 18.3. Then after isolating at home for two weeks, their mean copeptin levels and questionnaire scores both dropped markedly to 3.98 ± 1.28 pmol/L and 23.0 ± 7.95, respectively.
“Before we began this study, we observed that the healthcare providers who were going to be enrolled in the ICU were suffering anxiety problems,” said Demerdash. “Some were even trying to find excuses to postpone their shifts. Therefore, I decided, why not measure stress hormones and correlate them with stress questionnaire scores and the providers’ degree of anxiety. From this, I found that copeptin was significantly elevated in healthcare providers before they went into the ICU and that copeptin may be used as a potential biomarker for physiological strain during work in a stressful environment.”
AACC Annual Scientific Meeting registration is free for members of the media. Reporters can register online here: https://www.xpressreg.net/register/aacc0921/media/landing.asp
Abstract A-151: Evaluation of copeptin and psychological stress among healthcare providers during COVID pandemic will be presented during:
Scientific Poster Session
Tuesday, September 28
9:30 a.m. - 5 p.m. (presenting author in attendance from 1:30 - 2:30 p.m.)
Poster Hall, Exhibit Hall C
Georgia World Congress Center
About the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo
The AACC Annual Scientific Meeting offers 5 days packed with opportunities to learn about exciting science from September 26-30. Plenary sessions explore COVID-19 vaccines and virus evolution, research lessons learned from the pandemic, artificial intelligence in the clinic, miniaturization of diagnostic platforms, and improvements to treatments for cystic fibrosis.
At the AACC Clinical Lab Expo, more than 400 exhibitors will fill the show floor of the Georgia World Congress Center in Atlanta with displays of the latest diagnostic technology, including but not limited to COVID-19 testing, artificial intelligence, mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation.
Dedicated to achieving better health through laboratory medicine, AACC brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.aacc.org.